Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
Neoplasm Metastasis
DRUG: Zoledronic acid
Measurement of pain assessed by a Visual Analogue Scale (VAS), throughout the study
Quality of Life assessment at baseline and last visit, throughout the study
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.